Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Samantha Kendrick to Humans

This is a "connection" page, showing publications Samantha Kendrick has written about Humans.

 
Connection Strength
  
 
 
0.323
  
  1. McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329.
    View in: PubMed
    Score: 0.039
  2. Swafford K, Acharya B, Xu YZ, Raney T, McCrury M, Saha D, Frett B, Kendrick S. Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. Genes (Basel). 2022 06 25; 13(7).
    View in: PubMed
    Score: 0.035
  3. Shponka V, Reveles CY, Alam S, Jaramillo M, Maguire A, Rimsza LM, Kendrick S. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. AIDS. 2020 11 15; 34(14):2025-2035.
    View in: PubMed
    Score: 0.031
  4. Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. J Med Chem. 2017 08 10; 60(15):6587-6597.
    View in: PubMed
    Score: 0.025
  5. Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch. 2017 Jan; 470(1):113-117.
    View in: PubMed
    Score: 0.024
  6. Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, Rimsza LM. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma. 2016; 57(3):717-20.
    View in: PubMed
    Score: 0.022
  7. Kendrick SL, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Staudt LM, Chan WC, Steidl C, Grogan TM, Rimsza LM. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol. 2014 Oct; 45(10):2144-53.
    View in: PubMed
    Score: 0.020
  8. Kendrick S, Kang HJ, Alam MP, Madathil MM, Agrawal P, Gokhale V, Yang D, Hecht SM, Hurley LH. The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure. J Am Chem Soc. 2014 Mar 19; 136(11):4161-71.
    View in: PubMed
    Score: 0.019
  9. Kendrick S, Akiyama Y, Hecht SM, Hurley LH. The i-motif in the bcl-2 P1 promoter forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern. J Am Chem Soc. 2009 Dec 09; 131(48):17667-76.
    View in: PubMed
    Score: 0.015
  10. Chen J, Wang Z, Phuc T, Xu Z, Yang D, Chen Z, Lin Z, Kendrick S, Dai L, Li HY, Qin Z. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS Pathog. 2023 01; 19(1):e1011089.
    View in: PubMed
    Score: 0.009
  11. Chen J, Barrett L, Lin Z, Kendrick S, Mu S, Dai L, Qin Z. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. J Cell Mol Med. 2022 05; 26(9):2557-2565.
    View in: PubMed
    Score: 0.008
  12. Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022 02 08; 6(3):808-817.
    View in: PubMed
    Score: 0.008
  13. Chen J, Dai L, Kendrick S, Post SR, Qin Z. The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrob Agents Chemother. 2022 03 15; 66(3):e0239521.
    View in: PubMed
    Score: 0.008
  14. Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344.
    View in: PubMed
    Score: 0.008
  15. Mohan M, Kumar M, Samant R, Van Hemert R, Tian E, Desai S, van Rhee F, Thanendrarajan S, Schinke C, Suva LJ, Sharma S, Milad M, Kendrick S, Zangari M. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 05; 146:115876.
    View in: PubMed
    Score: 0.008
  16. Storey AJ, Naceanceno KS, Lan RS, Washam CL, Orr LM, Mackintosh SG, Tackett AJ, Edmondson RD, Wang Z, Li HY, Frett B, Kendrick S, Byrum SD. ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. Mol Omics. 2020 08 01; 16(4):316-326.
    View in: PubMed
    Score: 0.007
  17. Chen J, Kendrick S, Qin Z. Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses. 2019 12 16; 11(12).
    View in: PubMed
    Score: 0.007
  18. Maguire A, Chen X, Wisner L, Malasi S, Ramsower C, Kendrick S, Barrett MT, Glinsmann-Gibson B, McGrath M, Rimsza LM. Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. Int J Cancer. 2019 12 01; 145(11):3078-3088.
    View in: PubMed
    Score: 0.007
  19. Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015 Aug; 29(8):1702-12.
    View in: PubMed
    Score: 0.005
  20. Kang HJ, Kendrick S, Hecht SM, Hurley LH. The transcriptional complex between the BCL2 i-motif and hnRNP LL is a molecular switch for control of gene expression that can be modulated by small molecules. J Am Chem Soc. 2014 Mar 19; 136(11):4172-85.
    View in: PubMed
    Score: 0.005
  21. Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet. 2013 Jul-Aug; 206(7-8):257-65.
    View in: PubMed
    Score: 0.005
  22. Valentino C, Kendrick S, Johnson N, Gascoyne R, Chan WC, Weisenburger D, Braziel R, Cook JR, Tubbs R, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe E, Zhang W, Brunhoeber P, Nitta H, Grogan T, Rimsza L. Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am J Clin Pathol. 2013 Feb; 139(2):242-54.
    View in: PubMed
    Score: 0.005
  23. Brooks TA, Kendrick S, Hurley L. Making sense of G-quadruplex and i-motif functions in oncogene promoters. FEBS J. 2010 Sep; 277(17):3459-69.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.